FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $21.66, for a total value of $818,704.68. Following the completion of the transaction, the chief executive officer now owns 3,379,719 shares in the company, valued at approximately $73,204,713.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

FibroGen Inc. (NASDAQ:FGEN) opened at 22.15 on Friday. The stock’s market capitalization is $1.39 billion. FibroGen Inc. has a 52-week low of $14.38 and a 52-week high of $31.90. The firm has a 50-day moving average price of $19.03 and a 200 day moving average price of $18.48.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. FibroGen had a negative net margin of 61.90% and a negative return on equity of 48.66%. On average, equities research analysts predict that FibroGen Inc. will post ($1.25) EPS for the current year.

Separately, Credit Suisse Group AG reiterated a “buy” rating on shares of FibroGen in a report on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $33.25.

Several hedge funds and other institutional investors have recently bought and sold shares of FGEN. Vanguard Group Inc. boosted its position in FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares in the last quarter. BlackRock Fund Advisors boosted its position in FibroGen by 5.0% in the second quarter. BlackRock Fund Advisors now owns 2,053,134 shares of the biopharmaceutical company’s stock valued at $33,692,000 after buying an additional 96,844 shares in the last quarter. State Street Corp boosted its position in FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in FibroGen by 5.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,286,883 shares of the biopharmaceutical company’s stock valued at $21,118,000 after buying an additional 69,815 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in FibroGen by 0.3% in the second quarter. JPMorgan Chase & Co. now owns 1,282,804 shares of the biopharmaceutical company’s stock valued at $21,051,000 after buying an additional 3,482 shares in the last quarter. 49.82% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.